| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Zevra Therapeutics Inc. | Arimoclomol (EAP) - (NPC002) | Niemann-Pick disease type C (NPC) | Phase 3 | Data Released | Oral | Genetic Disorder |
| Zevra Therapeutics Inc. | KP1077 | Narcolepsy | Phase 3 | Trial Planned | oral | Neurology |
| Zevra Therapeutics Inc. | KP1077 (serdexmethylphenidate SDX) | Narcolepsy | Phase 3 | Trial Planned | oral | Neurology |
| Zevra Therapeutics Inc. | Arimoclomol | Sporadic Inclusion Body Myositis | Phase 2/3 | Oral | Neurology | |
| Zevra Therapeutics Inc. | ACER-2820 (emetine) | COVID-19 | Phase 2/3 | Trial Discontinued | Oral | COVID-19 |
| Zevra Therapeutics Inc. | Serdexmethylphenidate (SDX) - (KP1077) | Idiopathic hypersomnia (IH) | Phase 2 | Trial Completed | Oral | Neurology |
| Zevra Therapeutics Inc. | ACER-801 - (PORT-MAP) | Testosterone production for patients with prostate cancer | Phase 2 | Ongoing | Oral | Oncology |
| Zevra Therapeutics Inc. | ACER-801 - (POSH-MAP) | Hot flashes due to prostate cancer | Phase 2 | Ongoing | oral | Oncology |